Zai Lab appoints Richard Gaynor, MD as independent director and R&D Committee chair

Zai Lab Ltd

Gaynor is President & Chief R&D Officer at BioNTech US; previously 15 years at Lilly Oncology.
He receives $50K annual cash retainer for Board, plus $10K as R&D Committee chair, pro-rated to $6,904 for 2021.
Gaynor received an initial grant of 8,912 restricted ordinary shares on November 19, 2021.
CEO Samantha Du noted Gaynor and Scott Morrison were added to the Board in the past two months.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Gaynor

Independent Director

ZLAB · Zai Lab Ltd

Effective: 2021-11-19
Filed: November 22, 2021, 6:59 PM ET

On November 19, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Richard Gaynor as an independent director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Gaynor was appointed as Independent Director at Zai Lab Ltd.

Action: appointed
Role: Independent Director

Exact text from the filing

On November 19, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Richard Gaynor as an independent director, effective immediately.

View on SEC.gov

Zai Lab Ltd filing history →

Source: SEC EDGAR

accession 0001193125-21-335921

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.